Investigators identified blood plasma protein patterns linked to Alzheimer’s disease, dementia with Lewy bodies, and frontotemporal dementia, reporting a 21-protein panel. The work is described as leveraging proteomic profiling to map disease-associated signatures in peripheral blood, with the aim of improving stratification and earlier detection. The focus on multi-dementia differential markers is relevant for clinical development because it supports more precise patient enrichment and trial selection when imaging or invasive diagnostics are impractical. By targeting measurable plasma proteins, the approach is geared toward scalable biomarker workflows. The excerpt does not include performance metrics, validation cohorts, or assay platform details, but the panel-based strategy signals a push toward blood-based diagnostics for neurodegenerative disease subtyping.